We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

4 hedge funds and large institutions have $4.15M invested in Intra-Cellular Therapies Inc. in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 389 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 395 → 4 (-391)

100% less capital invested

Capital invested by funds: $13.6B → $4.15M (-$13.6B)

100% less funds holding in top 10

Funds holding in top 10: 52 → 0 (-52)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 389

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
-391
Holders Change %
-98.99%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
-52
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
389
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.26B
2
BlackRock
BlackRock
New York
-$1.15B
3
PCM
Pentwater Capital Management
Florida
-$685M
4
HI
HBK Investments
Texas
-$578M
5
Norges Bank
Norges Bank
Norway
-$472M
Name Holding Trade Value Shares
Change 		Change in
Stake
Legal & General Group
101
Legal & General Group
United Kingdom
– -$20.4M -154,271 Closed
GLAM
102
Gardner Lewis Asset Management
Pennsylvania
– -$19.2M -145,550 Closed
HCM
103
Highbridge Capital Management
New York
– -$18.8M -142,280 Closed
GKIM
104
GW&K Investment Management
Massachusetts
– -$18.6M -141,109 Closed
CCM
105
Cinctive Capital Management
New York
– -$18.5M -140,000 Closed
PA
106
Pinnacle Associates
New York
– -$17.9M -135,344 Closed
Janus Henderson Group
107
Janus Henderson Group
United Kingdom
– -$17.6M -133,352 Closed
National Bank of Canada
108
National Bank of Canada
Quebec, Canada
– -$17.5M -133,000 Closed
Jane Street
109
Jane Street
New York
– -$17.5M -132,909 Closed
VI
110
Vestcor Inc
New Brunswick, Canada
– -$16.9M -128,319 Closed
RhumbLine Advisers
111
RhumbLine Advisers
Massachusetts
– -$16.5M -125,239 Closed
WP
112
Woodline Partners
California
– -$16.3M -123,750 Closed
M
113
Murchinson
Ontario, Canada
– -$15.8M -120,049 Closed
SFM
114
Soros Fund Management
New York
– -$15.4M -116,588 Closed
T. Rowe Price Associates
115
T. Rowe Price Associates
Maryland
– -$15.2M -115,424 Closed
BHMP
116
Bardin Hill Management Partners
New York
– -$14.1M -107,001 Closed
TC
117
Trium Capital
United Kingdom
– -$13.5M -102,105 Closed
O
118
Ossiam
France
– -$12.9M -98,000 Closed
SG Americas Securities
119
SG Americas Securities
New York
– -$12.4M -94,039 Closed
State Board of Administration of Florida Retirement System
120
State Board of Administration of Florida Retirement System
Florida
– -$12.2M -92,572 Closed
California State Teachers Retirement System (CalSTRS)
121
California State Teachers Retirement System (CalSTRS)
California
– -$12.2M -92,133 Closed
CCM
122
Chicago Capital Management
Illinois
– -$11.9M -90,200 Closed
GLF
123
Groupe la Francaise
France
– -$11.7M -88,438 Closed
HIM
124
HGC Investment Management
Ontario, Canada
– -$11.3M -85,800 Closed
Invesco
125
Invesco
Georgia
– -$11.2M -85,066 Closed
3 4
5
6 7

ITCI Hedge Fund Activity: Q2 2025 in Review

4 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2025, worth a combined $4.15M — down 100% from $13.6B a quarter earlier.

Sellers outnumbered buyers: 389 funds closed out of ITCI and 0 opened new positions — a net loss of 389 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $1.26B sold.

  • 4 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2025, down from 395 in Q1 2025.
  • Funds reported $4.15M of Intra-Cellular Therapies Inc. stock for Q2 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2025 and 389 closed out, a net change of -389 holders.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2025 was Vanguard Group, an estimated $1.26B sold.

Based on aggregated 13F filings for Q2 2025.